AstraZeneca’s biggest event of the year, a trial evaluating the Imfinzi and tremelimumab combination in the Progression Free Survival (PFS) for lung cancer patients (in a study called MYSTIC), has failed in the first round, wiping out over £10bn from AstraZeneca’s market cap (share price fell by 15%) on 27 July. The combination could not beat chemotherapy at stopping disease progression in PD-L1 patients. Although the final study, assessing Overall Survival (OS), is still un
31 Jul 2017
MYSTIC’s devastating fiasco dwarfs everything
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MYSTIC’s devastating fiasco dwarfs everything
AstraZeneca PLC (AZN:LON) | 10,689 -6841 (-0.6%) | Mkt Cap: 165,702m
- Published:
31 Jul 2017 -
Author:
Kamla Singh -
Pages:
4
AstraZeneca’s biggest event of the year, a trial evaluating the Imfinzi and tremelimumab combination in the Progression Free Survival (PFS) for lung cancer patients (in a study called MYSTIC), has failed in the first round, wiping out over £10bn from AstraZeneca’s market cap (share price fell by 15%) on 27 July. The combination could not beat chemotherapy at stopping disease progression in PD-L1 patients. Although the final study, assessing Overall Survival (OS), is still un